StreetInsider.com News Articles

Form 10-Q SKINVISIBLE, INC. For: Sep 30

Thu, 13 Nov 2025 14:48:00 -0500

si-local-file:///var/storage/secattach/20251113/25606158.html

Form 10-Q SKINVISIBLE, INC. For: Sep 30

Thu, 13 Nov 2025 14:48:00 -0500

si-local-file:///var/storage/secattach/20251113/25606158.html

Ovation Science enhances Skinvisible partnership for obesity treatments

Thu, 18 Sep 2025 05:00:15 -0500

Ovation Science Inc. (CSE: OVAT, OTC: OVATF) announced an enhanced strategic partnership with Skinvisible Pharmaceuticals Inc. (OTCQB: SKVI) to develop cannabinoid delivery technology for the obesity market, according to a company statement.

The partnership builds on an original licensing agreement from September 29, 2017, and centers on Skinvisible's Invisicare technology for polymer delivery systems targeting cannabinoid-based therapeutic products. Ovation maintains exclusive worldwide rights to manufacture, distribute, market and promote licensed products using the delivery technology with cannabinoids.

The collaboration includes access to a recently filed PCT patent application titled "Transdermal Delivery Composition for Delivery of at least one Glucose Controlling Agent, and

Ovation Science and Skinvisible Pharmaceuticals Enhance Their Strategic Partnership in the Obesity Market with Innovative Cannabinoid Delivery Technology with New Developments and Patent Protection

Thu, 18 Sep 2025 05:00:00 -0500

VANCOUVER, BC AND LAS VEGAS, NV / ACCESS Newswire / September 18, 2025 / Ovation Science Inc. (CSE:OVAT)(OTC:OVATF) ("Ovation" or the "Company"), today announced an enhanced strategic partnership with Skinvisible Pharmaceuticals, Inc. (OTCQB:SKVI) ("Skinvisible") to leverage patent-pending Invisicare^® topical and transdermal cannabis developments in the obesity market. The agreement will enhance the strategic partnership for innovative cannabinoid delivery technology with new developments and patent protection. MARKET Opportunity: The Global obesity therapy market by 2035 could reach US $150 billion U.S. dollars) (Morgan Stanley 2025).

Ovation and Skinvisible are building upon their

Ovation Science and Skinvisible Pharmaceuticals Enhance Their Strategic Partnership in the Obesity Market with Innovative Cannabinoid Delivery Technology with New Developments and Patent Protection

Thu, 18 Sep 2025 05:00:00 -0500

Ovation and Skinvisible are building upon their

Form 10-Q SKINVISIBLE, INC. For: Jun 30

Wed, 13 Aug 2025 15:53:00 -0500

si-local-file:///var/storage/secattach/20250813/25195866.html

Form 10-Q SKINVISIBLE, INC. For: Jun 30

Wed, 13 Aug 2025 15:53:00 -0500

si-local-file:///var/storage/secattach/20250813/25195866.html

Form 10-Q SKINVISIBLE, INC. For: Mar 31

Wed, 14 May 2025 14:20:00 -0500

si-local-file:///var/storage/secattach/20250514/24796143.html

Form 10-Q SKINVISIBLE, INC. For: Mar 31

Wed, 14 May 2025 14:20:00 -0500

si-local-file:///var/storage/secattach/20250514/24796143.html

Form 10-K SKINVISIBLE, INC. For: Dec 31

Mon, 14 Apr 2025 16:56:00 -0500

si-local-file:///var/storage/secattach/20250414/24637173.html

Form 10-K SKINVISIBLE, INC. For: Dec 31

Mon, 14 Apr 2025 16:56:00 -0500

si-local-file:///var/storage/secattach/20250414/24637173.html

Form NT 10-K SKINVISIBLE, INC. For: Dec 31

Mon, 31 Mar 2025 13:19:00 -0500

si-local-file:///var/storage/secattach/20250331/24573301.html

Form NT 10-K SKINVISIBLE, INC. For: Dec 31

Mon, 31 Mar 2025 13:19:00 -0500

si-local-file:///var/storage/secattach/20250331/24573301.html

Form 8-K SKINVISIBLE, INC. For: Jan 23

Thu, 23 Jan 2025 15:21:00 -0500

si-local-file:///var/storage/secattach/20250123/24240739.html

Form 8-K SKINVISIBLE, INC. For: Jan 23

Thu, 23 Jan 2025 15:21:00 -0500

si-local-file:///var/storage/secattach/20250123/24240739.html

Skinvisible Reports Licensee Success in Netherton Syndrome Clinical Studies

Thu, 23 Jan 2025 05:30:00 -0500

LAS VEGAS, NV / ACCESS Newswire / January 23, 2025 / Skinvisible Pharmaceuticals, Inc. ("Skinvisible" or "the Company"), (OTCQB:SKVI), an innovative topical and transdermal pharmaceutical research and development company, with proprietary Invisicare® drug delivery technology, today announces significant achievements in 2024 and 2025, through its licensee Quoin Pharmaceuticals' progress in Netherton Syndrome treatment.

Skinvisible granted Quoin an exclusive, royalty-bearing license to its technology for use in select rare skin diseases and for the right to use its proprietary formula for Netherton Syndrome. Netherton Syndrome is a hereditary disorder affecting the skin, hair, and

Skinvisible Reports Licensee Success in Netherton Syndrome Clinical Studies

Thu, 23 Jan 2025 05:30:00 -0500

Skinvisible Reports Licensee Success in Netherton Syndrome Clinical Studies

Thu, 23 Jan 2025 05:30:00 -0500

Skinvisible Reports Licensee Success in Netherton Syndrome Clinical Studies

Thu, 23 Jan 2025 05:30:00 -0500

Form 10-Q SKINVISIBLE, INC. For: Sep 30

Tue, 19 Nov 2024 10:33:00 -0500

si-local-file:///var/storage/secattach/20241119/24003524.html

Form 10-Q SKINVISIBLE, INC. For: Sep 30

Tue, 19 Nov 2024 10:33:00 -0500

si-local-file:///var/storage/secattach/20241119/24003524.html

Form NT 10-Q SKINVISIBLE, INC. For: Sep 30

Thu, 14 Nov 2024 16:26:00 -0500

si-local-file:///var/storage/secattach/20241114/23986764.html

Form NT 10-Q SKINVISIBLE, INC. For: Sep 30

Thu, 14 Nov 2024 16:26:00 -0500

si-local-file:///var/storage/secattach/20241114/23986764.html

Form 8-K SKINVISIBLE, INC. For: Oct 03

Thu, 03 Oct 2024 11:21:00 -0500

si-local-file:///var/storage/secattach/20241003/23799089.html

Form 8-K SKINVISIBLE, INC. For: Oct 03

Thu, 03 Oct 2024 11:21:00 -0500

si-local-file:///var/storage/secattach/20241003/23799089.html